Akebia Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Akebia Therapeutics, Inc. on June 3, 2021, regarding events occurring on June 2, 2021. The filing documents the results of the Company's Annual Meeting of Stockholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders at the Annual Meeting:
- Director Elections: Stockholders elected two Class I directors to serve until the 2024 annual meeting.
- Steven C. Gilman, Ph.D.: 64,824,176 votes for; 10,347,514 votes withheld.
- Cynthia Smith: 63,698,872 votes for; 11,472,818 votes withheld.
- Executive Compensation: The advisory vote on named executive officer compensation was approved.
- Votes For: 54,907,226
- Votes Against: 19,769,560
- Abstentions: 494,904
- Auditor Ratification: Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021.
- Votes For: 111,693,763
- Votes Against: 745,043
- Abstentions: 438,361
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation that Steven C. Gilman, Ph.D., and Cynthia Smith have officially joined the Board of Directors.
- Verification of the significant number of broker non-votes (37,705,477) recorded across all proposals.
- Confirmation that Ernst & Young LLP is the appointed auditor for the 2021 fiscal year.
- Review of the substantial "Votes Against" count (approx. 19.8 million) on the executive compensation advisory vote.